PharmaCyte Biotech, Inc.

- 30 DEC 2013
Dr. Mark L. Rabe Develops Charter for Scientific Advisory Board of Nuvilex’s Subsidiary, Medical Marijuana Sciences, Inc.
SILVER SPRING, Md., Dec. 30, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Mark L. Rabe, Chairman of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary Medical Marijuana Sciences, Inc., has developed a Charter and
Read more →
- Posted in
- News
- 19 DEC 2013
Nuvilex’s Provides Progress Update on Cell Cloning Being Performed by Inno Biologics
SILVER SPRING, Md., Dec. 19, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, provided an update today on the progress made by its contractor, Inno Biologics, regarding the cloning of the cancer-prodrug ifosfamide-activating cells that form the basis for the
Read more →
- Posted in
- News
- 12 DEC 2013
Nuvilex’s Preparations for Planned Late-Phase Clinical Trials Timely in Light of Increasing Incidence of Pancreatic Cancer
SILVER SPRING, Md., Dec. 12, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, commented today that ongoing preparations for its planned late-phase clinical trials appear to be timely as recent reports in the scientific literature point to an ever-increasing incidence
Read more →
- Posted in
- News
- 11 DEC 2013
Nuvilex’s Contractor, Inno Biologics, Employs Clone-Pix(TM) Technology in Cloning Cells for Future Clinical Trials
SILVER SPRING, Md., Dec. 11, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its contractor, Inno Biologics Sdn. Bhd., is using the Clone-Pix(TM)technology for the isolation and selection of clones preparatory to obtaining the large numbers of
Read more →
- Posted in
- News
- 09 DEC 2013
Nuvilex Holds High Level Strategic Meetings to Solidify Company Objectives and Plans for Future Research and Development
SILVER SPRING, Md., Dec. 9, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it recently held three days of meetings to solidify the objectives and plans of PharmaCyte Biotech for future research and development. The participants included the
Read more →
- Posted in
- News
- 07 NOV 2013
Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes
SILVER SPRING, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria
Read more →
- Posted in
- News
- 04 NOV 2013
Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
SILVER SPRING, MD–(Marketwired – Nov 4, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that cloning of the cancer-drug-activating cells required for PharmaCyte Biotech’s future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities. Following
Read more →
- Posted in
- News
- 17 SEP 2013
Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials
SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX) (“Company”), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Inno Biologics Sdn. Bhd. to generate cell clones that are the basis of the Company’s future Phase 3 cancer clinical trials.
Read more →
- Posted in
- News
- 11 SEP 2013
Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer
NEW YORK, NY–(Marketwired – Sep 11, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration’s (FDA) Fast Track program. Late last week Celgene announced that the FDA has approved its supplemental new drug application for ABRAXANE® when
Read more →
- Posted in
- News
- 10 SEP 2013
Nuvilex Contracts Fisher BioServices, Inc. for Long-Term Storage of Cells for Future Phase 3 Clinical Trials
SILVER SPRING, MD–(Marketwired – Sep 10, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) (Company), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Fisher BioServices, Inc. for the long-term storage of cells that will be required for its future Phase 3 and other cancer
Read more →
- Posted in
- News

Press Releases